Cellarity

Cellarity was founded by Flagship Pioneering, a venture capital firm that invests in the life sciences sector. By combining network biology, AI, and technology, Cellarity has created a drug discovery platform that develops drugs by studying and altering cell behavior. The company claims to be the first to pursue drug discovery based on understanding cell behavior, which aims to create medicine by targeting the full cellular and molecular complexity of diseases. The ability to do so should help the company significantly improve the success rate and speed of drug discovery. The startup claims that in just less than a year, it has been able to identify “nearly a dozen” lead drug candidates with in vivo proof-of-concept across multiple therapeutic areas.

As of March 2024, the company had four drug candidates in its internal pipeline which targets hematology and immunology diseases.  

Key customers and partnerships

In January 2024 , the company partnered with Novo Nordisk to develop new treatment approaches for cardiometabolic diseases.

Funding and financials

In October 2022 , the company raised USD 121 million in a Series C funding round led by Flagship Pioneering. The funds were expected to advance its drug discovery pipeline towards the clinic, further developing its platform, and growing its headcount.